Politics
Can Drugs Buy Us More Time? The Anti-Aging Race Is Losing
Peter Zeihan argues that current anti-aging and anti-Alzheimer's drugs, while promising for individuals, are unlikely to meaningfully alter the demographic and economic challenges posed by aging populations in the US and China. The timing of cognitive decline and the size of the relevant generations mean it may already be too late for pharmaceutical solutions to solve the core issues.